ADMA: שווי חברה לרווח נקי ADMA Biologics Inc

ADMA Biologics owns raw material collection centers and patents, creating barriers to entry for competitors. Revenues are based on the supply of antibodies to hospitals for the therapy of immunodeficiencies. The success of immunoglobulins has ensured a liquidity surplus and margin growth. The company's P/E time series confirms these fundamentals, while 15.70 forms the current metric value, allowing for an assessment of the business value relative to earnings.

The P/E ratio relates the market capitalization of ADMA Biologics (ADMA) to its net income, measuring the cost of one dollar of current earnings in the eyes of investors. High expectations for profit growth here clash with operational dependence on plasma collection centers and competitive pressure, making the company's P/E value a key indicator of asset overvaluation should risks arise in immunoglobulin production.